We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Horizon (HZNP) Up on Initial Talks of Buyout by Pharma Giants
Read MoreHide Full Article
Horizon Therapeutics plc announced that it has held highly preliminary discussions with big pharma companies like Sanofi (SNY - Free Report) , Janssen, a subsidiary of J&J (JNJ - Free Report) and Amgen (AMGN - Free Report) , which may or may not lead to its potential acquisition by any of these giant drugmakers.
Horizon said that in accordance with Irish Takeover Rules, the possible bidders must say whether they intend to make an offer or not latest by Jan 10, 2023.
However, there is no certainty that any acquisition offer will be made.
Shares of Horizon were up 30.5% in after-hours trading on Tuesday following the announcement of the news. However, the stock has declined 26.9% so far this year compared with the industry’s decline of 19.9%.
Image Source: Zacks Investment Research
Horizon is engaged in developing medicines for treating rare autoimmune and severe inflammatory diseases. The company reports financial results under two segments, Orphan and Inflammation.
Horizon’s biggest drug, Tepezza, was approved by the FDA in early 2020 as a treatment for patients with thyroid eye disease (TED). With this nod, Tepezza became the first FDA-approved medicine for the treatment of active TED, a serious and vision-threatening rare autoimmune disease.
Horizon’s other marketed drugs include Krystexxa, Actimmune, Procysbi and Ravicti, which are approved for a range of rare diseases. HZNP is currently working on the label expansion of these drugs.
In the first nine months of 2022, Horizon’s total sales amounted to $2.68 billion while Tepezza generated sales worth $1.47 billion, reflecting an increase of 21% and 37%, respectively, on a year-over-year basis.
Horizon’s recent growth trajectory probably attracted the interest of big healthcare companies like Sanofi, J&J and Amgen, who often seek buyouts to expand their foothold in the market. All these companies have had a portfolio of rare-disease therapies, which is likely to diversify from such acquisitions.
It remains to be seen whether a deal materializes or not from any of the possible offerors for the potential buyout of Horizon.
If a deal does materialize, it would probably be the biggest acquisition of late. Horizon’s market cap is around $18 billion and it could very well be offered more than $20 billion.
Image: Bigstock
Horizon (HZNP) Up on Initial Talks of Buyout by Pharma Giants
Horizon Therapeutics plc announced that it has held highly preliminary discussions with big pharma companies like Sanofi (SNY - Free Report) , Janssen, a subsidiary of J&J (JNJ - Free Report) and Amgen (AMGN - Free Report) , which may or may not lead to its potential acquisition by any of these giant drugmakers.
Horizon said that in accordance with Irish Takeover Rules, the possible bidders must say whether they intend to make an offer or not latest by Jan 10, 2023.
However, there is no certainty that any acquisition offer will be made.
Shares of Horizon were up 30.5% in after-hours trading on Tuesday following the announcement of the news. However, the stock has declined 26.9% so far this year compared with the industry’s decline of 19.9%.
Image Source: Zacks Investment Research
Horizon is engaged in developing medicines for treating rare autoimmune and severe inflammatory diseases. The company reports financial results under two segments, Orphan and Inflammation.
Horizon’s biggest drug, Tepezza, was approved by the FDA in early 2020 as a treatment for patients with thyroid eye disease (TED). With this nod, Tepezza became the first FDA-approved medicine for the treatment of active TED, a serious and vision-threatening rare autoimmune disease.
Horizon’s other marketed drugs include Krystexxa, Actimmune, Procysbi and Ravicti, which are approved for a range of rare diseases. HZNP is currently working on the label expansion of these drugs.
In the first nine months of 2022, Horizon’s total sales amounted to $2.68 billion while Tepezza generated sales worth $1.47 billion, reflecting an increase of 21% and 37%, respectively, on a year-over-year basis.
Horizon’s recent growth trajectory probably attracted the interest of big healthcare companies like Sanofi, J&J and Amgen, who often seek buyouts to expand their foothold in the market. All these companies have had a portfolio of rare-disease therapies, which is likely to diversify from such acquisitions.
It remains to be seen whether a deal materializes or not from any of the possible offerors for the potential buyout of Horizon.
If a deal does materialize, it would probably be the biggest acquisition of late. Horizon’s market cap is around $18 billion and it could very well be offered more than $20 billion.
Zacks Rank
Horizon currently carries a Zacks Rank #3 (Hold).You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.